Aptose Biosciences Inc. (APTOF)

Market Cap	4.31M +0.4%
Revenue (ttm)	n/a
Net Income	-27.56M
EPS	-10.79
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	636
Open	1.690
Previous Close	1.675
Day's Range	1.690 - 1.690
52-Week Range	0.842 - 1.850
Beta	0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 14
• Stock Exchange: OTCMKTS
• Ticker Symbol: APTOF

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 6, 2026

Data Sources Report a data error